Integrated cancer biotech Infinitopes secures £12.8m seed financing to enhance its Precision ImmunomicsTM antigen discovery technologies to target fiv
Funding also supports the start of phase I/IIa study for lead vaccine, ITOP1Oxford, UK (April 30th, 2024) – Infinitopes Precision Immunomics, an integrated cancer biotech combining world leading platforms in precision antigen discovery with vaccine vectors capable of durably stimulating protective immune...